AK104 and low-dose radiation for advanced head and neck cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new immunotherapy drug called AK104 (cadonilimab) combined with low-dose radiation for people with head and neck or nasopharyngeal cancer that has come back or spread and no longer responds to first treatment. The goal is to see if this combination can shrink tumors or stop them from growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have head and neck squamous cell carcinoma or nasopharyngeal cancer that has returned or spread after first treatment.
- Your cancer has at least one measurable tumor (by scans).
- You are in generally good health (ECOG score 0-2) and doctors expect you to live more than 3 months.
- You have not received certain prior immunotherapies (anti-CTLA-4) or targeted drugs like lenvatinib.
- You do not have active infections, serious heart conditions, or autoimmune diseases that are not controlled.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares giving immunotherapy alone versus immunotherapy plus focused radiation before surgery for head and neck cancer. The goal is to see if adding radiation helps shrink the tumor and improve outcomes.
This trial tests a combination of chemotherapy directly into an artery, radiation, and immunotherapy for advanced head and neck cancer. It may offer a new treatment option for people whose cancer hasn't spread to other parts of the body.
This trial tests a new combination of two immunotherapy drugs (AK112 and AK117) versus the standard immunotherapy pembrolizumab for people with advanced head and neck cancer that hasn't been treated before.
This study tests a new combination treatment for head and neck cancer that has come back or spread and has a specific genetic change (CDKN2A mutation). The treatment combines an antibody-drug conjugate (a targeted therapy) with a CDK4/6 inhibitor (a drug that helps stop cancer cells from dividing). It may help people who have already tried standard treatments like immunotherapy or chemotherapy.
This trial tests if giving less radiation than usual is safe and effective for certain head and neck cancers after initial treatment with chemotherapy and immunotherapy. It aims to reduce side effects while still controlling the cancer.
This trial tests a new immunotherapy drug, AK104, for people with stage III non-small cell lung cancer that cannot be removed with surgery. It is for those who have finished chemoradiotherapy and have not gotten worse.
Hear when a new Head and Neck Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.